The use of genetic markers to identify lung cancer in fine needle aspiration samples

Rajbir K. Gill, Madeline F. Vazquez, Arin Kramer, Megan Hames, Lijuan Zhang, Kerstin Heselmeyer-Haddad, Thomas Ried, Konstantin Shilo, Claudia Henschke, David Yankelevitz, Jin Jen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: We seek to establish a genetic test to identify lung cancer using cells obtained through computed tomography - guided fine needle aspiration (FNA). Experimental Design: We selected regions of frequent copy number gains in chromosomes 1q32, 3q26, 5p15, and 8q24 in non - small cell lung cancer and tested their ability to determine the neoplastic state of cells obtained by FNA using fluorescent in situ hybridization. Two sets of samples were included. The pilot set included six paraffin-embedded, noncancerous lung tissues and 33 formalin-fixed FNA specimens. These 39 samples were used to establish the optimal fixation and single scoring criteria for the samples. The test set included 40 FNA samples. The results of the genetic test were compared with the cytology, pathology, and clinical follow-up for each case to assess the sensitivity and specificity of the genetic test. Results: Nontumor lung tissues had ≤4 signals per nucleus for all tested markers, whereas tumor samples had ≥5 signals per nucleus in five or more cells for at least one marker. Among the 40 testing cases, 36 of 40 (90%) FNA samples were analyzable. Genetic analysis identified 15 cases as tumor and 21 cases as nontumor. Clinical and pathologic diagnoses confirmed the genetic test in 15 of 16 lung cancer cases regardless of tumor subtype, stage, or size and in 20 of 20 cases diagnosed as benign lung diseases. Conclusions: A set of only four genetic markers can distinguish the neoplastic state of lung lesion using small samples obtained through computed tomography - guided FNA.

Original languageEnglish (US)
Pages (from-to)7481-7487
Number of pages7
JournalClinical Cancer Research
Volume14
Issue number22
DOIs
StatePublished - Nov 15 2008

Fingerprint

Fine Needle Biopsy
Genetic Markers
Lung Neoplasms
Lung
Tomography
Clinical Pathology
Tumor Biomarkers
Fluorescence In Situ Hybridization
Non-Small Cell Lung Carcinoma
Paraffin
Formaldehyde
Lung Diseases
Cell Biology
Neoplasms
Research Design
Chromosomes
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gill, R. K., Vazquez, M. F., Kramer, A., Hames, M., Zhang, L., Heselmeyer-Haddad, K., ... Jen, J. (2008). The use of genetic markers to identify lung cancer in fine needle aspiration samples. Clinical Cancer Research, 14(22), 7481-7487. https://doi.org/10.1158/1078-0432.CCR-07-5242

The use of genetic markers to identify lung cancer in fine needle aspiration samples. / Gill, Rajbir K.; Vazquez, Madeline F.; Kramer, Arin; Hames, Megan; Zhang, Lijuan; Heselmeyer-Haddad, Kerstin; Ried, Thomas; Shilo, Konstantin; Henschke, Claudia; Yankelevitz, David; Jen, Jin.

In: Clinical Cancer Research, Vol. 14, No. 22, 15.11.2008, p. 7481-7487.

Research output: Contribution to journalArticle

Gill, RK, Vazquez, MF, Kramer, A, Hames, M, Zhang, L, Heselmeyer-Haddad, K, Ried, T, Shilo, K, Henschke, C, Yankelevitz, D & Jen, J 2008, 'The use of genetic markers to identify lung cancer in fine needle aspiration samples', Clinical Cancer Research, vol. 14, no. 22, pp. 7481-7487. https://doi.org/10.1158/1078-0432.CCR-07-5242
Gill RK, Vazquez MF, Kramer A, Hames M, Zhang L, Heselmeyer-Haddad K et al. The use of genetic markers to identify lung cancer in fine needle aspiration samples. Clinical Cancer Research. 2008 Nov 15;14(22):7481-7487. https://doi.org/10.1158/1078-0432.CCR-07-5242
Gill, Rajbir K. ; Vazquez, Madeline F. ; Kramer, Arin ; Hames, Megan ; Zhang, Lijuan ; Heselmeyer-Haddad, Kerstin ; Ried, Thomas ; Shilo, Konstantin ; Henschke, Claudia ; Yankelevitz, David ; Jen, Jin. / The use of genetic markers to identify lung cancer in fine needle aspiration samples. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 22. pp. 7481-7487.
@article{2ab4c6d2f45b4ccdbdef2be320b4ab34,
title = "The use of genetic markers to identify lung cancer in fine needle aspiration samples",
abstract = "Purpose: We seek to establish a genetic test to identify lung cancer using cells obtained through computed tomography - guided fine needle aspiration (FNA). Experimental Design: We selected regions of frequent copy number gains in chromosomes 1q32, 3q26, 5p15, and 8q24 in non - small cell lung cancer and tested their ability to determine the neoplastic state of cells obtained by FNA using fluorescent in situ hybridization. Two sets of samples were included. The pilot set included six paraffin-embedded, noncancerous lung tissues and 33 formalin-fixed FNA specimens. These 39 samples were used to establish the optimal fixation and single scoring criteria for the samples. The test set included 40 FNA samples. The results of the genetic test were compared with the cytology, pathology, and clinical follow-up for each case to assess the sensitivity and specificity of the genetic test. Results: Nontumor lung tissues had ≤4 signals per nucleus for all tested markers, whereas tumor samples had ≥5 signals per nucleus in five or more cells for at least one marker. Among the 40 testing cases, 36 of 40 (90{\%}) FNA samples were analyzable. Genetic analysis identified 15 cases as tumor and 21 cases as nontumor. Clinical and pathologic diagnoses confirmed the genetic test in 15 of 16 lung cancer cases regardless of tumor subtype, stage, or size and in 20 of 20 cases diagnosed as benign lung diseases. Conclusions: A set of only four genetic markers can distinguish the neoplastic state of lung lesion using small samples obtained through computed tomography - guided FNA.",
author = "Gill, {Rajbir K.} and Vazquez, {Madeline F.} and Arin Kramer and Megan Hames and Lijuan Zhang and Kerstin Heselmeyer-Haddad and Thomas Ried and Konstantin Shilo and Claudia Henschke and David Yankelevitz and Jin Jen",
year = "2008",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-07-5242",
language = "English (US)",
volume = "14",
pages = "7481--7487",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - The use of genetic markers to identify lung cancer in fine needle aspiration samples

AU - Gill, Rajbir K.

AU - Vazquez, Madeline F.

AU - Kramer, Arin

AU - Hames, Megan

AU - Zhang, Lijuan

AU - Heselmeyer-Haddad, Kerstin

AU - Ried, Thomas

AU - Shilo, Konstantin

AU - Henschke, Claudia

AU - Yankelevitz, David

AU - Jen, Jin

PY - 2008/11/15

Y1 - 2008/11/15

N2 - Purpose: We seek to establish a genetic test to identify lung cancer using cells obtained through computed tomography - guided fine needle aspiration (FNA). Experimental Design: We selected regions of frequent copy number gains in chromosomes 1q32, 3q26, 5p15, and 8q24 in non - small cell lung cancer and tested their ability to determine the neoplastic state of cells obtained by FNA using fluorescent in situ hybridization. Two sets of samples were included. The pilot set included six paraffin-embedded, noncancerous lung tissues and 33 formalin-fixed FNA specimens. These 39 samples were used to establish the optimal fixation and single scoring criteria for the samples. The test set included 40 FNA samples. The results of the genetic test were compared with the cytology, pathology, and clinical follow-up for each case to assess the sensitivity and specificity of the genetic test. Results: Nontumor lung tissues had ≤4 signals per nucleus for all tested markers, whereas tumor samples had ≥5 signals per nucleus in five or more cells for at least one marker. Among the 40 testing cases, 36 of 40 (90%) FNA samples were analyzable. Genetic analysis identified 15 cases as tumor and 21 cases as nontumor. Clinical and pathologic diagnoses confirmed the genetic test in 15 of 16 lung cancer cases regardless of tumor subtype, stage, or size and in 20 of 20 cases diagnosed as benign lung diseases. Conclusions: A set of only four genetic markers can distinguish the neoplastic state of lung lesion using small samples obtained through computed tomography - guided FNA.

AB - Purpose: We seek to establish a genetic test to identify lung cancer using cells obtained through computed tomography - guided fine needle aspiration (FNA). Experimental Design: We selected regions of frequent copy number gains in chromosomes 1q32, 3q26, 5p15, and 8q24 in non - small cell lung cancer and tested their ability to determine the neoplastic state of cells obtained by FNA using fluorescent in situ hybridization. Two sets of samples were included. The pilot set included six paraffin-embedded, noncancerous lung tissues and 33 formalin-fixed FNA specimens. These 39 samples were used to establish the optimal fixation and single scoring criteria for the samples. The test set included 40 FNA samples. The results of the genetic test were compared with the cytology, pathology, and clinical follow-up for each case to assess the sensitivity and specificity of the genetic test. Results: Nontumor lung tissues had ≤4 signals per nucleus for all tested markers, whereas tumor samples had ≥5 signals per nucleus in five or more cells for at least one marker. Among the 40 testing cases, 36 of 40 (90%) FNA samples were analyzable. Genetic analysis identified 15 cases as tumor and 21 cases as nontumor. Clinical and pathologic diagnoses confirmed the genetic test in 15 of 16 lung cancer cases regardless of tumor subtype, stage, or size and in 20 of 20 cases diagnosed as benign lung diseases. Conclusions: A set of only four genetic markers can distinguish the neoplastic state of lung lesion using small samples obtained through computed tomography - guided FNA.

UR - http://www.scopus.com/inward/record.url?scp=58149330688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149330688&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-5242

DO - 10.1158/1078-0432.CCR-07-5242

M3 - Article

C2 - 19010865

AN - SCOPUS:58149330688

VL - 14

SP - 7481

EP - 7487

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -